{"search_session":{},"preferences":{"l":"fr","queryLanguage":"fr"},"patentId":"US_2010_0285020_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"147-847-030-793-668"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8676,"type":"PATENT","title":"New York University Patent Portforlio ","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":5145,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2015-11-12T00:15:20Z","updated":"2015-11-23T01:36:42Z","lastEventDate":"2015-11-23T01:36:42Z"},{"id":8877,"type":"PATENT","title":"New York Univ Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":15466,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8211,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners seperately = \"New York Univ\", \"New York University NOT \"state\" NOT \"city\" \", \"Univ New York\", \"NYU\".
Search Applicants and Owners seperately = \"New York Univ\", \"New York University NOT \"state\" NOT \"city\" \", \"Univ New York\", \"NYU\".
selecting a subject at risk for developing central nervous system leukemia;\n
providing a therapeutic agent that inhibits CCR7-CCL19 signaling; and\n
administering the therapeutic agent to the selected subject under conditions effective to prevent central nervous system leukemia in the selected subject."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein the subject at risk for developing central nervous system leukemia has T-cell acute lymphoblastic leukemia."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein the therapeutic agent is a CCL19 inhibitor selected from the group consisting of a nucleic acid molecule, an inhibitory peptide, an antibody, and a small molecule."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 3, wherein the CCL19 inhibitor is a human monoclonal antibody or an active binding fragment thereof."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein the therapeutic agent is a CCR7 antagonist selected from the group consisting of a nucleic acid molecule, an inhibitory polypeptide, an antibody, and a small molecule."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 5, wherein the CCR7 antagonist is a human monoclonal antibody or an active binding fragment thereof."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein the therapeutic agent is an integrin inhibitor."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 7, wherein the integrin inhibitor is an α4β1 integrin inhibitor selected from the group consisting of a nucleic acid molecule, an inhibitory polypeptide, an antibody, and a small molecule."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 8, wherein the α4β1 integrin inhibitor is an antibody that binds to α4."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 8, wherein the α4β1 integrin inhibitor is an antibody that binds to β1."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 8, wherein the α4β1 integrin inhibitor is an inhibitory peptide selected from the group consisting of an (X)CDPC peptide, an XC(Z)PC peptide, and a cyclic XCA(Z)C peptide."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, further comprising:\n
administering to the selected subject a therapeutic agent that inhibits Notch-1."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 12, wherein the therapeutic agent that inhibits Notch-1 is a gamma-secretase inhibitor selected from the group consisting of [(2S)-2-{[(3,5-Difluorophenyl)acetyl]amino}-N-[(3S)1- methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]propanamide] (CompE), N-[N-(3,5-difluorophenacetyl)-L-alanyl]-Sphenylglycine-t-butylester (DAPT), LY411575, (5S)-(t-Butoxycarbonylamino)-6-phenyl-(4R)hydroxy-(2R)benzylhexanoyl)-L-leu-L-phe-amide (L-685,458), L-852,647, MW167, WPE-III-31, LY450139, MRK003, R-flurbiprofen ([1,1′-Biphenyl]-4-acetic acid, 2-fluoro-alpha- methyl), NGX-555, CZC-1040, E2012, GSI-1, Begacestat (2-Thiophenesulfonamide, 5- chloro-N-[(1S)-313,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]-), NIC5-15, BACE Inhibitor, and CI-IF-5074."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1 further comprising:\n
administering a chemotherapeutic agent to the subject."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 14, wherein the chemotherapeutic agent is selected from the group consisting of cytarabine, vincristine, prednisone, daunorubicin, PEG asparaginase, methotrexate, and leucovorin."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["A method of treating T-cell acute lymphoblastic leukemia in a subject, said method comprising:\n
selecting a subject having T-cell acute lymphoblastic leukemia and administering a cocktail of chemotherapeutic agents and a therapeutic agent that inhibits CCR7-CCL19 signaling under conditions effective to treat T-cell acute lymphoblastic leukemia in the selected subject."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 16, wherein the cocktail of chemotherapeutic agents comprises two or more chemotherapeutic agents selected from the group consisting of cytarabine, vincristine, prednisone, daunorubicin, PEG asparaginase, methotrexate, and leucovorin."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 16, wherein the therapeutic agent is a CCL19 inhibitor selected from the group consisting of a nucleic acid molecule, an inhibitory peptide, an antibody, and a small molecule."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 18, wherein the CCL19 inhibitor is a human monoclonal antibody or an active binding fragment thereof."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 16, wherein the therapeutic agent is a CCR7 antagonist selected from the group consisting of a nucleic acid molecule, an inhibitory peptide, an antibody, and a small molecule."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 20, wherein the CCR7 antagonist is a human monoclonal antibody or an active binding fragment thereof."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 16, wherein the therapeutic agent is an integrin inhibitor."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 22, wherein the integrin inhibitor is an α4β1 integrin inhibitor selected from the group consisting of a nucleic acid molecule, an inhibitory peptide, an antibody, and a small molecule."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 23, wherein the α4β1 integrin inhibitor is an antibody that binds to α4."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 23, wherein the α4β1 integrin inhibitor is an antibody that binds to β1."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 23, wherein the α4β1 integrin inhibitor is an inhibitory peptide selected from the group consisting of an (X)CDPC peptide, an XC(Z)PC peptide, and a cyclic XCA(Z)C peptide."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["A method of treating an immune system disorder in a subject, said method comprising:\n
selecting a subject having an immune system disorder;\n
providing a therapeutic agent that inhibits CCR7-CCL19 signaling; and\n
administering the therapeutic agent to the selected subject under conditions effective to treat the immune system disorder in the selected subject."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 27, wherein the immune system disorder is an acute or chronic inflammatory condition."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 27, wherein the immune system disorder is an autoimmune condition."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 27, wherein the therapeutic agent is a CCL19 inhibitor selected from the group consisting of a nucleic acid molecule, an inhibitory peptide, an antibody, and a small molecule."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 30, wherein the CCL19 inhibitor is a human monoclonal antibody or an active binding fragment thereof."],"number":31,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 27, wherein the therapeutic agent is a CCR7 antagonist selected from the group consisting of a nucleic acid molecule, an inhibitory polypeptide, an antibody, and a small molecule."],"number":32,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 32, wherein the CCR7 antagonist is a human monoclonal antibody or an active binding fragment thereof."],"number":33,"annotation":false,"title":false,"claim":true},{"lines":["A method of identifying a compound capable of preventing leukocyte transendothelial cell migration, said method comprising:\n
providing one or more candidate compounds;\n
contacting the one or more candidate compounds with a CCR7-CCL19 signaling system;\n
determining whether the one or more candidate compounds inhibits CCR7-CCL19 mediated signaling; and\n
identifying the one or more candidate compounds which inhibit CCR7-CCL19 mediated signaling as a compound capable of preventing leukocyte transendothelial cell migration."],"number":34,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 34, wherein the one or more candidate compounds is selected from the group consisting of an inhibitory CCL19 peptide, a small molecule CCR7 antagonist, an antibody directed to CCL19, and an antibody directed to CCR7."],"number":35,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 34, further comprising:\n
administering the identified compound capable of preventing leukocyte transendothelial cell migration to a subject at risk for developing central nervous system leukemia."],"number":36,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 36, wherein the subject at risk for developing central nervous system leukemia has T-cell acute lymphoblastic leukemia."],"number":37,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 34, further comprising:\n
administering the identified compound capable of preventing leukocyte transendothelial cell migration to a subject having an immune system disorder."],"number":38,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}